| Specialty Retail Industry | Consumer Discretionary Sector | Mr. Erez Israeli M.B.A. CEO | MSE Exchange | INE089A01023 ISIN |
| India Country | 27,048 Employees | 10 Jul 2025 Last Dividend | 28 Oct 2024 Last Split | 11 Apr 2001 IPO Date |
Dr. Reddy's Laboratories Limited is a multinational pharmaceutical company with a comprehensive operational scope that spans globally. Founded in 1984 and headquartered in Hyderabad, India, the company operates with a diversified portfolio that includes engaging in the manufacture and marketing of a wide range of pharmaceutical products. Its business operations are strategically segmented into Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others. Each of these segments plays a critical role in the company's commitment to health care, contributing to its status as an integrated pharmaceutical entity. Dr. Reddy's Laboratories not only focuses on meeting the pharmaceutical needs of today but also invests in research and development to innovate for the future, ensuring they remain at the forefront of the pharmaceutical industry globally.
This segment underscores the company's commitment to accessibility in healthcare by manufacturing and marketing both prescription and over-the-counter pharmaceutical products. These products, offered as both branded and generic formulations, ensure therapeutic efficacy akin to original branded versions. The segment also encompasses Dr. Reddy's endeavors in the biologics business, highlighting its role in biosimilars and biopharmaceuticals, reducing the cost of biologic therapies while increasing access to these vital treatments.
As a backbone to the pharmaceutical manufacturing process, the PSAI segment supplies active pharmaceutical ingredients (APIs) and intermediates, crucial for the production of various medications. This segment not only serves the internal needs of Dr. Reddy's Laboratories but also caters to the global market, offering contract research services to develop new compounds and providing custom synthesis for other pharmaceutical companies. The portfolio includes the manufacturing and selling of APIs, steroids, and other intermediates tailored to specific customer specifications.
Under this category, Dr. Reddy's Laboratories extends its expertise into the realms of oncology and inflammation with the aim of developing novel therapies. This segment also includes the company's efforts in research and development of differentiated formulations, signifying a focus on innovation. Additionally, it encompasses the provision of digital healthcare solutions and IT-enabled business support services, aiming to leverage technology to enhance healthcare deliverables and operational efficiency within the pharmaceutical domain.
The company's comprehensive product and service offerings span across various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, demonstrating Dr. Reddy's Laboratories' extensive impact on global healthcare.